

## New CEO commentary: "The scientific role of commercialization"

On PHI's website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco "The evolution of Phase Holographic Imaging from a research idea to publicly traded company", see [www.phiab.se/commentary/commentary-180204](http://www.phiab.se/commentary/commentary-180204).

For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74

E-mail: [ir@phiab.se](mailto:ir@phiab.se)

Web: [www.phiab.se](http://www.phiab.se)

*Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.*